StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
TPT and HCPCS code issuance reduce reimbursement friction and enable hospital outpatient reimbursement, likely boosting near-term demand and utilization of PYLARIFY TruVu; phased rollout mitigates supply risk but still provides a meaningful upgrade to LNTH's PSMA PET growth trajectory.
What happened, with direct paths to the underlying reporting
CMS has granted Transitional Pass-Through (TPT) status and a permanent HCPCS code for PYLARIFY TruVu, effective October 1, 2026, enabling separate reimbursement in hospital outpatient settings. This milestone supports broader Medicare access and could lift demand for LNTH's PSMA PET imaging franchise as TruVu improves manufacturing efficiency and geographic reach. A phased rollout should mitigate near-term supply risks while expanding patient access.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.